The EvoLVcell stable producer cell line generation platform reportedly reduces variability and produces fewer impurities.

This dual strategy—developing serum-free media and engineering immortalized cell lines—addresses two of the most pressing challenges in cultured meat production: cost reduction and stable scalability.

For the first time, researchers at the University of British Columbia have demonstrated how to reliably produce an important type of human immune cell—known as helper T cells—from stem cells in a ...

WUHAN, HUBEI PROVINCE, CHINA, February 15, 2026 /EINPresswire.com/ — In the complex landscape of life science research, selecting the right cellular model is a ...

Research on preventing type 1 diabetes often focuses on limiting the autoimmune response that destroys the body’s ability to produce its own insulin. A new technology developed by scientists at the ...

NYBCe and CZ Biohub will derive iPSC lines from cord blood's immune cells, creating shared, broadly compatible resources for cell therapy, disease modelling, and AI-driven drug development.

Cancer immunotherapy is a strategy that turns the patient’s own immune cells into a “search-and-destroy” force that attacks the tumor’s cells. The “search” immune cells are the dendritic cells, which ...

Although Chinese hamster ovary (CHO) cells have dominated therapeutic protein expression systems for decades, biomanufacturers still must deal with their inconsistent expression levels and varying ...

New York Blood Center Enterprises’ (NYBCe) Lindsley F. Kimball Research Institute (LFKRI) today announced a scientific collaboration with Biohub to develop optimized methodologies for deriving induced ...